EyePoint Pharmaceuticals

EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in the development and commercialization of therapeutics that treat eye disorders. It offers FDA-approved sustained-release treatments in ophthalmology under the DEXYCU, ILUVIEN, Verisome, Retisert, and Durasert brands. The company was founded in 1987 and is headquartered in Watertown, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

EyePoint Pharmaceuticals reports revenue growth and strategic expansion plans

EyePoint Pharmaceuticals showcased strong revenue growth, promising product pipeline with EYP-1901, and strategic partnerships for future expansion. While facing challenges in trial design and molecule size for sustained release, the company is well-positioned for growth with opportunities for collaborations and improved margins in 2023.

EyePoint Pharmaceuticals reports strong Q1 performance and advances revolutionary eye disease treatment

EyePoint Pharmaceuticals (EYPT) delivered a strong Q1 2023 performance, driven by progress in clinical trials for EYP-1901 and a robust YUTIQ franchise.
The company's focus on innovation, safety, and market needs positions EYP-1901 as a potential game-changer in treating chronic eye diseases.
While challenges exist in trial modifications and regulatory considerations, opportunities abound in market expansion, collaboration potential, and regulatory progress.
Overall, EyePoint Pharmaceuticals (EYPT) showcases promising growth prospects and a commitment to advancing novel treatments for retinal diseases.

EyePoint Pharmaceuticals reports Q2 revenue growth amidst operational challenges

EyePoint Pharmaceuticals' Q2 2023 performance showed revenue growth but with significant operating expenses leading to a net loss.
Strengths lie in the progress of EYP-1901, positive data presentations, and a well-capitalized position for future endeavors.
Challenges include financial losses, concerns about patient response variability, and Phase III trial design complexities.
Opportunities exist in exploring funding avenues, post-approval studies, and strategic cost management for Phase III trials.

EyePoint Pharmaceuticals reports Q3 revenue growth and advances drug pipeline

EyePoint Pharmaceuticals showcased progress in drug development and revenue generation in Q3 2023.
The company is strategically positioned with a strong cash position to fund operations into 2025.
Focus on innovative drug delivery mechanisms and collaborations for sustained release treatments.

EyePoint Pharmaceuticals excels in Q4, poised for retinal disease innovation

EyePoint Pharmaceuticals delivered strong financial results, showcased promising trial outcomes for EYP-1901 in wet AMD, and addressed key analyst inquiries regarding market dynamics and competition. With a focus on innovation and strategic leadership appointments, the company is poised for transformative developments in retinal disease treatments.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

- Q 3 20 20 net product revenues are estimated to be between $ 5.5 - $ 5.9 million, as healthcare facilities began reopening from COVID-19 closures -

EyePoint Pharmaceuticals Announces Preliminary Net Product Revenue for Third Quarter 2020

WATERTOWN, Mass., Aug.  24, 2020  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced that it has entered into a purchase and marketing agreement with Vantage Outsourcing for DEXYCU® (dexamethasone intraocular suspension) 9%. Vantage Outsourcing is a leading cataract surgical service provider to a variety of hospitals, ambulatory surgery centers (ASCs), and physicians. The agreement will enable customers in the Vantage Outsourcing network, which spans over a 25+ state service area, to incorporate DEXYCU into their surgical protocols for treating ocular inflammation associated with cataract surgery.

EyePoint Pharmaceuticals Secures New Purchase and Marketing Agreement with Vantage Outsourcing for DEXYCU®

EyePoint Pharmaceuticals (EYPT) news from yesterday concerning a massive deal has EYPT stock continuing to climb higher on Friday.
The post EyePoint Pharmaceuticals News: Why EYPT Stock Is Soaring 21% Today appeared first on InvestorPlace.

EyePoint Pharmaceuticals News: Why EYPT Stock Is Soaring 21% Today

WATERTOWN, Mass., Aug.  20, 2020  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, and Ocumension Therapeutics, a China-based ophthalmic pharmaceutical platform company, today announced the expansion of their exclusive license agreements for the development and commercialization of YUTIQ® and DEXYCU® in certain Asian markets. Under the expanded agreements, Ocumension has made a one-time $9.5 million payment to EyePoint for rights to commercialize both products under their own brand names in South Korea and other jurisdictions across Southeast Asia and as the full and final prepayment of all remaining development, regulatory, and commercial sale milestone payments under the original license agreements.

EyePoint Pharmaceuticals Receives $9.5 Million in Upfront Cash from Ocumension Therapeutics Under Expanded License Agreements

EyePoint Pharmaceuticals, Inc.'s (EYPT) CEO Nancy Lurker on Q2 2020 Results - Earnings Call Transcript

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) moved lower by 2.5% in pre-market trading after the company reported Q4 results.

EyePoint Pharmaceuticals: Q4 Earnings Insights

- Total revenues of $4.1 million and net product revenues of $3.7 million impacted by COVID-19 pandemic -

EyePoint Pharmaceuticals Reports Second Quarter 2020 Financial Results and Highlights Recent Corporate Developments

- Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers - - Collaboration to bring DEXYCU to ImprimisRx’s established customer base of ophthalmologists, hospitals, and ambulatory surgical centers -

EyePoint Pharmaceuticals and Harrow Health’s ImprimisRx Announce U.S. Commercial Alliance for DEXYCU®

WATERTOWN, Mass., July  29, 2020  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, will report results for its second quarter 2020 on Wednesday, August 5, 2020. Management will host a conference call to review the results at 8:30 AM ET on the same day.

EyePoint Pharmaceuticals Announces Second Quarter 2020 Financial Results Release Date and Conference Call Information

WATERTOWN, Mass., July  27, 2020  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a pharmaceutical company committed to developing and commercializing innovative ophthalmic products, today announced the presentation of data supporting YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18 mg three-year micro-insert for chronic, non-infectious uveitis affecting the posterior segment of the eye. The data were presented in two oral sessions at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting held July 24 – 26, 2020.

EyePoint Pharmaceuticals Presents Data Supporting YUTIQ® at the American Society of Retina Specialists (ASRS) Virtual Annual Meeting

- World-renowned retina specialist to lead EYP-1901 development efforts and support expansion of EyePoint’s ocular disease pipeline -

EyePoint Pharmaceuticals Expands Executive Leadership Team with the Appointment of Jay S. Duker, M.D.

BIO-key Int.

Cocrystal Pharma

Second Sight Medical Products

Recro Pharma

Despite valuations looking expensive, the markets are in a good place as of this morning, despite the cases for coronavirus spiking over the weekend. Some may say the market is getting ahead of itself.

Top Stocks To Short As Dow Jumps Amid Coronavirus Spikes

Agenus

Atomera

Axcella Health Inc

Miragen Therapeutics

If you’re looking to hedge against a coming pullback in the markets, we've used our deep learning algorithms and AI to identify the Top Shorts today.

Stocks To Hedge Your Portfolio With Amid Rising Coronavirus Cases

EyePoint Pharmaceuticals (EYPT) saw a big move last session, as its shares jumped more than 7% on the day, amid huge volumes.

EyePoint Pharmaceuticals (EYPT) Surges: Stock Moves 7.4% Higher

Bandwidth

Capital One

Guardion Health Sciences Inc

Heat Biologics

The market is powering through its third consecutive day of massive gains. Whether the market is too optimistic has been on the minds of many, considering how unstable the economy has been this year.

Top Stocks To Short As Stock Market Surges

Brickell Biotech Inc

Digital Ally Inc

MannKind

As tensions continue to rise both domestically and internationally, taking a short position isn't a bad idea. Our deep learning algorithms have identified these 5 companies as the top stocks to short today.

Top Stocks To Short As Market Ignores Widespread Protests

EyePoint Pharmaceuticals, Inc. (EYPT) CEO Nancy Lurker on Q1 2020 Results - Earnings Call Transcript

EyePoint Pharmaceuticals (EYPT) delivered earnings and revenue surprises of -10.00% and 7.83%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?

EyePoint Pharmaceuticals (EYPT) Reports Q1 Loss, Tops Revenue Estimates

Shares of EyePoint Pharmaceuticals (NASDAQ:EYPT) were flat in pre-market trading after the company reported Q3 results.

EyePoint Pharmaceuticals: Q3 Earnings Insights

EyePoint Still Has A Very Promising Future

- Proactive Efforts to Mitigate Spread and Protect Safety and Well-being of Patients, Treating Physicians, Employees and Our Communities -

EyePoint Pharmaceuticals Provides COVID-19 Pandemic Business Operations Update

EyePoint Pharmaceuticals' (EYPT) CEO Nancy Lurker on Q4 2019 Results - Earnings Call Transcript

36-month data showed uveitis eye flare recurrence rate of 46.5% in YUTIQ-treated eyes vs. 75.0% in sham eyes, a 40% reduction 36-month data showed uveitis eye flare recurrence rate of 46.5% in YUTIQ-treated eyes vs. 75.0% in sham eyes, a 40% reduction

EyePoint Pharmaceuticals Announces Positive Topline 36-month Follow-up Data for Second Phase 3 Study of YUTIQ®

EyePoint's stock offering isn't sitting well with shareholders today. Here's why.

Why EyePoint Pharmaceuticals Is Cratering Today

WATERTOWN, Mass., Feb.  21, 2020  (GLOBE NEWSWIRE) -- EyePoint Pharmaceuticals, Inc. (NASDAQ: EYPT), a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products today announced the pricing of an underwritten public offering of 15,000,000 shares of its common stock at a public offering price of $1.45 per share. The gross proceeds of the offering to the Company are expected to be approximately $21,750,000, before deducting the underwriting discounts and commissions and other estimated offering expenses. In addition, EyePoint granted the underwriters a thirty-day option to purchase up to an additional 2,250,000 shares of common stock at the public offering price, less underwriting discounts and commissions. The closing of the offering is expected to occur on or about February 25, 2020, subject to the satisfaction of customary closing conditions. Guggenheim Securities is acting as sole book-running manager for the offering. Laidlaw & Company (UK) Ltd. is acting as co-manager for the offering. EyePoint intends to use the net proceeds of the offering to continue to fund the commercialization and expand the access of DEXYCU® (dexamethasone intraocular suspension) 9% and YUTIQ® (fluocinolone acetonide intravitreal implant) 0.18, and for general corporate purposes, which may include working capital, capital expenditures, research and development expenditures related to the advancement of EYP-1901 for retinal diseases and our other product candidates, clinical trial expenditures, acquisitions of new technologies, products or businesses in ophthalmology, and investments. The securities described above are being offered by the Company pursuant to a shelf registration statement on Form S-3 (No. 333-228581) previously filed with and declared effective by the Securities and Exchange Commission (SEC) on December 11, 2018. A preliminary prospectus supplement relating to the offering was filed with the SEC on February 20, 2020 and is available on the SEC’s website at http://www.sec.gov. The final prospectus supplement relating to and describing the terms of the offering will be filed with the SEC and also will be available on the SEC’s website. Before investing in the offering, you should read each of the prospectus supplement and the accompanying prospectus relating to the offering in their entirety as well as the other documents that the Company has filed with the SEC that are incorporated by reference in the prospectus supplement and the accompanying prospectus relating to the offering, which provide more information about the Company and the offering. Copies of the final prospectus supplement, when available, and accompanying prospectus relating to the offering may be obtained from Guggenheim Securities, LLC Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017 or by telephone at (212) 518-5548, or by email at GSEquityProspectusDelivery@guggenheimpartners.com. This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.  About EyePoint Pharmaceuticals EyePoint Pharmaceuticals, Inc. is a biopharmaceutical company committed to developing and commercializing innovative ophthalmic products in indications with high unmet medical need to help improve the lives of patients with serious eye disorders. The Company currently has two commercial products: DEXYCU®, the first approved intraocular product for the treatment of postoperative inflammation, and YUTIQ®, a three-year treatment of chronic non-infectious uveitis affecting the posterior segment of the eye. The Company's pipeline leverages its proprietary bioerodible Durasert™ technology for extended intravitreal drug delivery including EYP-1901 targeting wet age-related macular degeneration, diabetic retinopathy and retinal vein occlusion. EyePoint Pharmaceuticals is headquartered in Watertown, Massachusetts with offices in Basking Ridge, New Jersey.

News for EyePoint Pharmaceuticals Stock (EYPT)